Back to top
more

Akorn, Inc. (AKRX)

(Delayed Data from NSDQ)

$2.85 USD

2.85
1,371,052

+0.14 (5.17%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.86 (%) 5:22 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Brokerage Reports

0 items in cart

Akorn, Inc. [AKRX]

Reports for Purchase

Showing records 1 - 20 ( 90 total )

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 1

04/02/2020

Company Report

Pages: 2

Terminating coverage

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 2

02/14/2020

Company Report

Pages: 2

WhatÂ’s Akorn Worth? Let the Bidding Begin- Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 3

11/01/2019

Company Report

Pages: 2

Q3 Results Show Further Progress, but Debt Decision Looms - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 4

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for AKRX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 5

08/02/2019

Company Report

Pages: 2

Raising Estimates After Q2 Improvements

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 6

08/02/2019

Company Report

Pages: 2

Raising Estimates After Q2 Improvements - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 7

05/08/2019

Company Report

Pages: 2

A Positive First Step on a Long and Uncertain Road

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 8

03/01/2019

Company Report

Pages: 2

Back to Work - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 9

01/10/2019

Company Report

Pages: 2

We maintain our Hold recommendation

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 10

12/24/2018

Company Report

Pages: 2

AKRX Names New CEO - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 11

12/10/2018

Company Report

Pages: 2

Loses Appeal Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 12

11/08/2018

Company Report

Pages: 2

Margins Continue to Erode in Q3 - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 13

10/02/2018

Company Report

Pages: 2

Judgement Day - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 14

04/24/2018

Company Report

Pages: 2

''''You Lied to Me'''' Return of the MAC - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 15

08/22/2017

Company Report

Pages: 2

Sector Fears Seep into Deal - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 16

05/05/2017

Company Report

Pages: 2

No Surprises in Q1 - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 310.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 17

04/25/2017

Company Report

Pages: 2

Akorn Chooses Road to Germany - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 18

04/10/2017

Company Report

Pages: 2

Fresenius Looking to Get Serious? - Buy

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 19

03/02/2017

Company Report

Pages: 2

Ephedrine Weighs on 2017 Outlook - Buy

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 20

01/04/2017

Daily Note

Pages: 65

2017 Best Ideas

Provider: G.RESEARCH, LLC

Price: 150.00

Research Provided by a Third Party